Cochlear Limited Company Overview and Financial Performance

Cochlear Limited is a global leader in implantable hearing solutions. Founded in 1982 by a group of Australian entrepreneurs, the company has grown to become a household name in the medical device industry.

Cochlear's headquarters is located in Sydney, Australia, and it has a presence in over 100 countries worldwide. The company's innovative products have helped millions of people around the world regain their hearing.

Cochlear's success can be attributed to its commitment to research and development, with a strong focus on improving the lives of people with hearing impairments. The company has a diverse range of products, including cochlear implants, bone anchored hearing systems, and auditory implants.

Cochlear Limited is a publicly traded company listed on the Australian Securities Exchange (ASX) under the ticker code COH.

On a similar theme: Harbinger Knowledge Products

Cochlear Limited offers a range of implantable hearing solutions for children and adults worldwide. The company's products include cochlear implant systems, sound processor upgrades, bone conduction systems, and other products.

Take a look at this: Sumitomo Precision Products

Their cochlear implant systems integrate complex technologies to deliver sound to the auditory nerve and brain, using external sound processors and internal implantable electrodes. These systems can provide easier management of program settings, better understanding of speech in challenging listening environments, and a reduction in size and weight with a new ergonomic design.

Cochlear's sound processing technology is compatible with both its cochlear implants and bone-conduction implants, and has improved significantly over the years. The Nucleus 8 (N8) sound processor, for example, features SmartSound iQ 2, which enables dual microphones to capture speech and filter out background noise.

Here are some of the key features of Cochlear's sound processing technology:

Their implantable electrode technology has also improved significantly, with electrodes becoming thinner and easier to insert into the cochlea to minimize damage to the delicate internal structures of the inner ear.

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers a range of products, including cochlear implant systems, sound processor upgrades, bone conduction systems, and accessories.

Additional reading: Cochlear Implants Waterproof

Cochlear's cochlear implant systems, such as the Nucleus 8, integrate advanced technologies like sound processing and implantable electrode technology. These systems are designed to provide easier management of program settings, better understanding of speech in challenging listening environments, and improved sound quality.

The company's sound processing technology works with both cochlear implants and bone-conduction implants, using advanced algorithms to improve speech recognition and reduce background noise. Cochlear's latest improvements for the Nucleus 8 include SmartSound iQ 2, SCAN 2, ForwardFocus, and Beam technology.

Cochlear's implanted electrodes are highly reliable and designed to be used for life, with the company constantly improving their design and functionality. The Profile series of implantable electrodes, for example, are only 3.9 mm in thickness and fit snugly under the scalp.

The company also offers bimodal solutions, coordinating sound processing between a hearing aid in one ear and a cochlear implant in the other. This is made possible through Cochlear's alliance with GN ReSound, one of the world's top-five hearing aid manufacturers.

Here are some of the key features of Cochlear's products:

Cochlear's products are designed to be user-friendly, with features like wireless connectivity and smartphone app control. The Nucleus Smart App, for example, allows users to adjust sound processor settings and monitor battery life directly from their iPhone or Android device.

The company's commitment to innovation has led to the development of new technologies like the Kanso 2 cochlear implant headpiece, which offers a standalone sound processing solution without the need for a separate sound processor.

You might enjoy: Puget Sound Bridge and Dredging Company

Cochlear Limited has a global presence with subsidiaries and joint ventures around the world.

The company's associated companies and holding company can be viewed online, providing a comprehensive list of its domestic and international entities.

Cochlear Limited's subsidiaries and joint ventures play a crucial role in the development and distribution of its products and technologies.

The company's international presence is significant, with subsidiaries and joint ventures in various countries.

Expand your knowledge: Paccar Subsidiaries

Cochlear Limited's financial performance is a key aspect of its overall health and success.

The company's revenue has been steadily increasing over the years, with a total revenue of $2.34 billion as of the last reported period.

A closer look at the company's profitability reveals a profit margin of 16.60%, indicating that it is able to maintain a significant portion of its revenue as profit.

The return on assets (ROA) and return on equity (ROE) are also notable, standing at 11.73% and 20.52% respectively, suggesting that the company is generating a decent return on its assets and equity.

Here are some key financial metrics for Cochlear Limited:

As of October 3, 2025, the trailing total returns for COH.AX include dividends or other distributions. The benchmark is the S&P/ASX 200 (^AXJO).

Let's take a look at the performance of Cochlear Limited. The company's trailing total returns as of the mentioned date are available, but the exact figure is not provided in the given article sections.

If you're interested in comparing Cochlear Limited's performance with its peers, you can select up to 4 stocks for a 5-year return analysis. This feature allows you to analyze similar companies using key performance metrics.

Here's a summary of Cochlear Limited's key financial ratios and data on financial growth:

These ratios provide a clearer picture of Cochlear Limited's performance and financial health.

Let's take a closer look at the valuation measures of these companies. Market Cap for the first company is a whopping 18.54B, while the second company's Market Cap is significantly lower at 12.18B.

The Enterprise Value for the first company is also substantial, at 18.50B, and is very close to its Market Cap. For the second company, the Enterprise Value is slightly lower at 12.15B.

The Trailing P/E ratio for the first company is 47.70, indicating that investors are willing to pay a premium for its shares. This ratio is slightly lower for the second company, at 46.56.

The Forward P/E ratio for the first company is 41.67, suggesting that investors expect its earnings to grow in the coming years. The second company's Forward P/E ratio is also reasonable, at 40.65.

Here's a summary of the key valuation measures for both companies:

The Price/Sales ratio for both companies is relatively high, at 7.92 and 7.73 respectively, indicating that investors are willing to pay a premium for their shares. The Price/Book ratio is also high, at 9.51 and 9.28 respectively, suggesting that investors are valuing their intangible assets highly.

Suggestion: Log 9 Materials

Cochlear Limited's financial performance is impressive, with a trailing total return of 10/3/2025, which may include dividends or other distributions. The company's benchmark is the S&P/ASX 200 (^AXJO).

The company's balance sheet is strong, with total cash of $275.7M and a total debt/equity ratio of 12.08%. This suggests that Cochlear Limited has a solid financial foundation.

One notable financial metric is the levered free cash flow, which stands at $97.44M. This indicates that the company is generating a significant amount of cash from its operations.

Here's a summary of Cochlear Limited's key financial metrics:

Cochlear Limited's profitability is also noteworthy, with a profit margin of 16.60% and a return on equity of 20.52%. This suggests that the company is able to generate significant profits from its operations.

The company's revenue has been steadily increasing, with a total revenue of $2.34B in the most recent quarter. This is a significant increase from the previous quarter's revenue of $1.9557B.

Cochlear Limited has been involved in several recalls of its products over the years.

The company recalled some of its CI22M (Nucleus 22) implants in 1995 due to failures with the internal power supply caused by the capacitors being installed backwards, which resulted in less than 10 devices needing to be explanted.

The company's proactive approach to recalling faulty products is a testament to its commitment to patient safety.

In 2011, Cochlear voluntarily recalled all Nucleus CI500 implants after reports of the devices shutting down. The cause of the malfunction and number of devices affected is unknown.

The recall resulted in a significant drop in the company's shares, with a 27% decline, likely due to the fact that the product being recalled made up 70% of Cochlear's total company sales.

Here are some key facts about Cochlear's recalls:

Cochlear Limited has a number of major shareholders, including its ultimate parent.

The company's registered business details show that it is a publicly listed entity.

If you're interested in investing in Cochlear Limited, you can find its financial details, including its profit and loss account and balance sheet, in our Enterprise Financials section.

At Cochlear Limited, the key personnel can be categorized by position type and title. The company outlines its key personnel in this way, providing a clear understanding of who's in charge.

The Chairman of the Board is one such key personnel, responsible for guiding the company's overall direction.

The Managing Director and Chief Executive Officer is another key personnel, overseeing the day-to-day operations of the company.

The Chief Financial Officer is also a key personnel, handling the company's financial matters.

Consider reading: Financial Review Fast Starters

Cochlear Limited's major shareholders include its ultimate parent, which is outlined in the company's major shareholders section.

The largest shareholders of Cochlear Limited are its significant investors who have a substantial stake in the company.

The ultimate parent of Cochlear Limited is the entity that has the most significant influence over the company's management and operations.

Cochlear Limited's major shareholders play a crucial role in shaping the company's direction and making key decisions.

We can learn more about Cochlear Limited's major shareholders by reviewing the company's major shareholders section.

Investor Information: Why Buy an Enterprise Profile?

IBISWorld provides in-depth profiles on thousands of leading enterprises across Australia and New Zealand, including Cochlear Limited.

These profiles are thoroughly researched, reliable, and current, enabling you to make faster, better business decisions.

You can expect to find comprehensive information on the enterprise, including its history, brands, products, and financial statements.

Key personnel, subsidiaries, shareholders, and ownership structure are also detailed in the profile.

IBISWorld's expert reports are a valuable resource for investors, helping you stay up-to-date on business and industry trends.

Here's a breakdown of what you can expect to find in an IBISWorld enterprise profile:

To get a clearer picture of Cochlear Limited's performance, we need to compare their financial ratios and growth to their peers in the industry.

Comparing Cochlear Limited to similar companies using key performance metrics can provide valuable insights into their strengths and weaknesses.

You can select up to 4 stocks to analyze using the "Compare To: COH.AX" feature, which allows you to see how Cochlear Limited stacks up against its competitors.

Consider reading: Compare Travel Insurance

Comparing COH.AX to similar companies is a great way to get a better understanding of its performance. To do this, you can select up to 4 stocks to analyze using key performance metrics.

The benchmark for COH.AX is the S&P/ASX 200 [XJO] (^AXJO), which provides a standard against which to measure its performance.

For more insights, see: Holley Performance Products

Benchmarking is a powerful tool to gauge a company's performance. By comparing Cochlear Limited's financial ratios and growth to peers in their industries of operation, you can get a clearer picture of performance.

To do this, you can use online tools that allow you to compare companies side by side. For example, you can compare Cochlear Limited's financials to those of similar companies listed on the Australian Securities Exchange, such as COH.AX.

Selecting up to 4 stocks for comparison can help you identify trends and patterns that might not be immediately apparent. This can be especially useful for investors looking to make informed decisions about their portfolio.

By analyzing key performance metrics, you can gain a deeper understanding of a company's strengths and weaknesses. This can also help you identify areas where a company may be lagging behind its competitors.

Comparing companies like Cochlear Limited to their peers can provide valuable insights and help you make more informed decisions.

Cochlear Limited has a comprehensive financial history, but we don't have access to all the details.

Their enterprise financials include a profit and loss account with revenue, interest, and audit fees.

We can also see their balance sheet, which breaks down into current and non-current assets and liabilities, as well as shareholders' equity.

Cochlear Limited was founded in 1982 by Dr. Graeme Clark, an Australian otolaryngologist.

The company's early success was largely due to its innovative cochlear implant technology, which was first implanted in a human in 1978.

Cochlear Limited's major projects have included the development of the Nucleus 22 cochlear implant, which was introduced in 1984.

Past announcements from Cochlear Limited have included the company's expansion into new markets and the launch of new products, such as the Nucleus 5 cochlear implant in 2009.

The company has also been involved in several mergers and acquisitions over the years, including the acquisition of the Advanced Bionics cochlear implant business in 2016.

Related reading: New London Ship and Engine Company

The fiscal year ends on September 30th, marking the close of a 12-month period for financial record-keeping.

Businesses and organizations use the fiscal year to track their income and expenses, with the goal of making a profit. This helps them make informed decisions about investments and resource allocation.

A company's fiscal year can be different from the calendar year, with some businesses choosing to end their fiscal year on June 30th or December 31st. This allows them to align their financial reporting with their business operations.

The fiscal year end is a critical time for businesses, as it requires them to review their financial performance and make adjustments for the upcoming year. This can involve budgeting, forecasting, and making strategic decisions to improve profitability.

Many businesses use the fiscal year end to review their financial statements, including the balance sheet and income statement. This helps them identify areas for improvement and make data-driven decisions about their operations.

For more insights, see: Magellan Financial Group